Ensuring the best chance of success for new technologies through development of evidence generation plans requires multi-stakeholder involvement with patients, regulators, and health technology assessment (HTA) bodies. Critical to this process is optimization of plans via Integrated Scientific Advice (ISA) by which medical treatment developers get valuable feedback from regulators, HTA bodies, and payers. This enables developers to create a robust evidence packages relevant to all stakeholders. Access the full paper here.
You are here: / / [White Paper] Integrated Scientific Advice and Multiple Stakeholder Engagements